Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Drugs Vaccine-against-Gram-negative-bacterial-infections

 Antigenic proteins of Borrelia burgdorferi
It is an object of the present invention to provide a means for detecting mammals previously or ...


 Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
We claim: 1. An isolated DNA molecule consisting of a nucleotide sequence as shown in FIG. 3 for ACA...


 Compositions and methods using the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein C (OspC) for the diagnosis and prevention of lyme disease
The present invention is directed to an isolated, immunogenic polypeptide fragment of OspC of B...


 Isolation and use of solid tumor stem cells
The invention claimed is: 1. A method for determining the capability of a test compound to inhibit ...


 Hair analysis method
OF THE INVENTION In accordance with the present invention, a method is provided that permits the ...


 Method for retarding or precluding Alzheimer's dementia
OF THE INVENTION The markers which are targeted according to the method of the invention are those ...


 Streptococcus pneumoniae polynucleotides and sequences
OF ILLUSTRATIVE EMBODIMENTS The present invention is based on the sequencing of fragments of the S...


 Protection against dental caries
I claim: 1. A process for producing an antigen preparation, for use in the reduction or prevention ...


 High molecular weight polymer-based prodrugs
In one aspect of the invention, compositions of formula (I) are provided: ##STR2## wherein: D is a ...


 Macrocyclic NS-3 serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
OF PREFERRED EMBODIMENTS In one embodiment, the present invention discloses compounds of Formula I ...


 Vaccine against Gram-negative bacterial infections

Details
Inventors: Bhattacharjee, Apurba; Cross, Alan; Sadoff, Jerald; Zollinger, Wendell;
Assignee: United States of America as represented by the Secretary of the Army (Washington, DC)
Primary Examiner: Devi; S.
Assistant Examiner:
Attorney, Agent or Firm: Arwine; Elizabeth, Harris; Charles H., Moran; John Francis

A vaccine, effective in inducing the production of antibodies with which to immunize a second subject passively against infection by Gram-negative bacteria and LPS-mediated pathology, comprises a non-covalent polyvalent complex formed between purified, detoxified LPS derived from E. coli and purified outer membrane protein derived from N. meningitidis. The same vaccine will also actively immunize a host subject against Gram-negative bacterial infections and LPS-mediated pathology. Meningococcal infections are included among those Gram-negative bacterial infections protected against by the vaccine.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS According to the present invention, a non-covalent, polyvalent complex between purified, detoxified LPS ("DLPS") derived from E.
coli and purified outer membrane protein derived from N.
meningitidis is provided which, when injected into a host subject, actively immunizes the host subject against Gram-negative bacteria and LPS-mediated pathology.
Post-immune serum or plasma from the host subject, or specific polyclonal antibody purified from these fluids, can be administered to a second subject, passively immunizing the second subject against infection by Gram-negative bacteria and LPS-induced pathology.
The preferred strain of E.
coli from which to prepare purified and detoxified LPS endotoxin is an E.
coli J5 (Rc chemotype) strain.
Native J5 LPS may be purchased from List Biological Labs, Inc.
, Campbell, Calif.
For purification purposes it is preferred that the LPS preparation contain less than about 1% protein and less than about 1% nucleic acid.
By "purified E.
coli LPS" is meant LPS suitable for use in the invention vaccine prepared by sonicating native LPS in an alkaline solution, heating the solution at 65° C.
, neutralizing the cooled solution to pH 7.
0, removing released fatty acids and remaining native LPS by Sephadex G-50 chromatography, and collecting the purified, detoxified DLPS.
As determined in a standard rabbit pyrogenicity test, this method reduces the pyrogenicity of LPS preparations, and thus are also referred to as DLPS.
An embodiment of this procedure is described in Example 1 below.
A preferred strain of meningococcus is N.
meningitidis group B.
The outer membrane protein therefrom (hereinafter "GBOMP") is prepared as described in Zollinger et al.
, J.
Clin.
Invest.
63:836 (1079), and U.
S.
Pat.
No.
4,707,543 (1987), the contents of which are incorporated herein by reference.
Briefly, meningococcal group B cells are warmed to about 55 to 60° C.
for a brief period, and disrupted in a shearing device such as OMNIMIX, sold by DuPont Instruments (Newtown, Conn



Related patents
  Modified human hemoglobin, blood substitutes containing the same, and vectors for expressing the modified hemoglobin
The present invention relates to modified .beta.-chains of human hemoglobin having an oxygen binding affinity equal to or less than natural human hemoglobin. Preferably, ...
  Inhibitor of stem cell proliferation and uses thereof
The present invention relates to polypeptides which are inhibitors of stem cell proliferation ("INPROL") and their use. The present invention includes an inhibitor of ...
  Inhibitor of stem cell proliferation and uses thereof
The present invention relates to an inhibitor of stem cell proliferation (INPROL) characterized by the following properties: (a) Specific activity (IC.sub.50) less than ...
  Method of inhibiting angiogenesis using secreted proteins
Isolated Proteins Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The ...
  Balanced extraction system
The present invention is a device wherein matter to be extracted which contains various available components is kept in a state almost like a natural environment or, for ...
  Compounds for the treatment of hepatoma
What is claimed is: 1. The method of treatment of a living subject affected by hepatoma which consists of administering to said subject by the oral route up to three ...
  5ht2 agonists for controlling IOP and treating glaucoma
1. A method for lowering or controlling intraocular pressure or treating glaucoma which comprises administering a composition comprising a pharmaceutically effective ...
  Insect resistant tomato and potato plants
We claim: 1. A chimeric gene capable of expressing in a plant cell comprising in sequence: (a) a promoter which functions in plants to cause the production of RNA; (b) a ...
  Insect resistant plants
In accordance with one aspect of the present invention, there has been provided a method for producing genetically transformed plants which exhibit toxicity toward C...
  Hybrid toxin
What is claimed is: 1. An insecticidal Bacillus thuringiensis hybrid toxin fragment, comprising: a) at a C-terminus of said fragment, domain m of III first Cry protein; ...

0.014

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved